Crystal and application of sulfonamide pyrimidine derivative

The ETA receptor antagonizes the crystallization of sulfonamide pyrimidine derivatives, which solves the problem of renal injury caused by excessive activation of ETA receptors in IgA nephropathy, achieves effective remission of renal injury, and demonstrates efficient bioavailability and medicine Generation dynamics properties.

CN118908944APending Publication Date: 2024-11-08CHIA TAI TIANQING PHARMA GRP CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410569299.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-08
Filing Date
2024-05-08
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The excessive activation of ETA receptors in IgA nephropathy leads to renal injury and renal fibrosis. The existing treatment methods are limited in effect and lack effective drug-targeted treatments.

Method used

A crystal of sulfonamide pyrimidine derivative was developed to alleviate renal damage and fibrosis through the antagonism of ETA receptors. The crystals were prepared by solvent precipitation and separation methods, and combined with X-ray powder diffraction, DSC and TGA technologies to ensure that Crystallization purity and stability.

Benefits of technology

The compound showed high-efficiency ETA receptor antagonism activity, good bioavailability and pharmacokinetic properties, able to alleviate renal injury in rats, and provides potential treatment options for IgA nephropathy and related renal diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118908944A_ABST
    Figure CN118908944A_ABST
Patent Text Reader

Abstract

The invention provides a crystal of a sulfamido pyrimidine derivative and application thereof, and particularly discloses a crystal of a compound shown as a formula (I) and a preparation method and application thereof. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Citation of Related Applications

[0002] This application claims priority and benefits of Chinese invention patent application No. 202310512370.2 filed with the State Intellectual Property Office of China on May 8, 2023, and all the contents disclosed in the application are incorporated herein by reference in their entirety. Technical Field

[0003] The present disclosure relates to a crystal and use of a sulfonylaminopyrimidine derivative, and in particular to a crystal of a compound of formula (I), a preparation method thereof and use thereof. Background Art

[0004] IgA nephropathy is one of the most common primary glomerulonephritis, accounting for about 25%-50% of primary glomerular diseases in my country. And the incidence of IgA nephropathy is higher in young and middle-aged people. Among patients over 20 years old, about 40% of patients will develop end-stage renal disease.

[0005] Endothelin (ET) is a naturally occurring bicyclic peptide consisting of 21 amino acids present in plasma. Under various pathophysiological factors (aging, diabetes, insulin resistance, obesity, immune system activation, dyslipidemia, reactive oxygen formation, nitric oxide deficiency, etc.), endothelial cells are induced to synthesize and release endothelin-1 (ET-1). Endothelin has two known receptors, namely endothelin A receptor (ETR-A) and endothelin B receptor (ETR-B). Endothelin binds to ETR-A on vascular smooth muscle cells and causes vasoconstriction, cell proliferation and extracellular matrix deposition. Endothelin binds to ETR-B on endothelial cells and can promote vasodilation, anti-cell proliferation and anti-fibrosis by mediating the production of nitric oxide. Endothelin acts on the ETA receptor of renal cells to produce different physiological effects, including vasoconstriction, endothelial cell damage, vascular wall thickening, tissue infiltration, inflammatory response, mesangial cell proliferation, podocyte damage, etc. Excessive activation of renal ETA receptors can cause renal damage and renal fibrosis, leading to the occurrence and progression of chronic kidney disease, FSGS, and IgA nephropathy. Summary of the invention

[0006] In one aspect, the present disclosure provides a crystal of a compound of formula (I) or a pharmaceutically acceptable salt thereof,

[0007]

[0008] in,

[0009] Z 1 Select from N or CR Z1 ;

[0010] Z 2 Select from N or CR Z2 ;

[0011] R Z1 or R Z2 Each is independently selected from H, halogen, -OH, -NH2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, di-C 1-6 Alkylamino, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, halogenated C 1-6 Alkylthio, halo 1-6 Alkylamino, or halogenated di-C 1-6 Alkylamino;

[0012] X is selected from O or NH;

[0013] Ring A is selected from a Substituted: 3-12 membered cycloalkyl or 3-12 membered heterocycloalkyl;

[0014] R a are each independently selected from halogen, -OH, oxo, -NH2, -CN, -C(O)R a1 、-C(O)NR a1 R a2 、-NR a1 C(O)R a2 、-NHC(O)NR a1 R a2 、-NR a1 C(O)OR a2 、-OC(O)R a1 、-C(O)OR a1 、-OC(O)OR a1 、-OC(O)NR a1 R a2 , -C 1-6 Alkylene C(O)NR a1 R a2 , -C 1-6 Alkylene NR a1 C(O)R a2 , -C 1-6 AlkyleneNHC(O)NR a1 R a2 , -C 1-6 Alkylene NR a1 C(O)OR a2 , -C 1-6 Alkylene OC(O)Ra1 , -C 1-6 Alkylene C(O)OR a1 , -C 1-6 Alkylene OC(O)NR a1 R a2 , or optionally 1 or more R a3 Substituted with the following groups: C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 5-10 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl;

[0015] R a1 , R a2 Each independently selected from H or C 1-6 alkyl;

[0016] R a3 Each is independently selected from halogen, -OH, -NH2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, di-C 1-6 Alkylamino, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, halogenated C 1-6 Alkylthio, halo 1-6 Alkylamino, or halogenated di-C 1-6 Alkylamino;

[0017] L is selected from a single bond, -O-, -S-, -NH-, -C(O)-, or optionally substituted by one or more R L Substituted with the following groups: -CH2-, -N(C 1-6 alkyl)-, or -CH(C 1-6 alkyl)-;

[0018] R L Each is independently selected from halogen, -OH, -NH2, -CN, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, di-C 1-6 Alkylamino, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, halogenated C 1-6 Alkylthio, halo 1-6 Alkylamino, or halogenated di-C 1-6 Alkylamino;

[0019] Ring D is selected from optionally one or more Rb Substituted: 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 5-10 membered carbocyclyl, 5-10 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl;

[0020] R b Each is independently selected from halogen, -OH, -NH2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, di-C 1-6 Alkylamino, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, halogenated C 1-6 Alkylthio, halo 1-6 Alkylamino, or halogenated di-C 1-6 Alkylamino;

[0021] Y 1 is selected from -O-, -S-, or -NH-;

[0022] Y 2 is selected from -O-, -S-, -NH-, -SO2-, -NHSO2-, -SO2NH-, -NHSO2NH-, -C(O)NH-, -NHC(O)-, -OC(O)NH-, -NHC(O)O-, or -NHC(O)NH-;

[0023] m is selected from 1, 2, 3, 4, 5, or 6;

[0024] Ring C is selected from 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 5-10 membered carbocyclyl, 5-10 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl;

[0025] n is selected from 0, 1, 2, 3, or 4;

[0026] R1 is independently selected from halogen, -OH, -NH2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, di-C 1-6 Alkylamino, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, halogenated C 1-6 Alkylthio, halo 1-6 Alkylamino, or halogenated di-C 1-6 Alkylamino;

[0027] R2 is selected from H, halogen, -OH, -NH2, -CN, or is optionally replaced by one or more R2a Substituted with the following groups: C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, di-C 1-6 Alkylamino, 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 5-10 membered carbocyclyl, 5-10 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl;

[0028] R 2a Each is independently selected from oxo, halogen, -OH, -NH2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, di-C 1-6 Alkylamino, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, halogenated C 1-6 Alkylthio, halo 1-6 Alkylamino, or halogenated di-C 1-6 Alkylamino;

[0029] R Z1 , R Z2 ,X,R a , R a1 , R a2 , R a3 , R L , R b , R1, R2, R 2a , Ring A, Ring D or Ring C is optionally substituted with one or more substituents.

[0030] In some embodiments of the present disclosure, the crystals of the compound of formula (I) or a pharmaceutically acceptable salt thereof are selected from the crystals of the compound of formula (II), the compound of formula (III), the compound of formula (IV), the compound of formula (V), the compound of formula (VI), or a pharmaceutically acceptable salt thereof:

[0031]

[0032]

[0033] In another aspect, the present disclosure provides a crystal of a compound of formula (II), a crystal of a compound of formula (III), a crystal of a compound of formula (IV), a crystal of a compound of formula (V), or a crystal of a compound of formula (VI).

[0034] The present disclosure also provides a method for preparing the crystal of the compound of formula (II), the crystal of the compound of formula (III), the crystal of the compound of formula (IV), the crystal of the compound of formula (V), or the crystal of the compound of formula (VI): comprising the step of precipitating the compound of formula (II), the compound of formula (III), the compound of formula (IV), the compound of formula (V), or the compound of formula (VI) in a solvent. Further, it also includes a separation step.

[0035] In another aspect, the present disclosure provides a crystal of a compound of formula (IV),

[0036]

[0037] In some embodiments of the present disclosure, the crystal of the compound of formula (IV) is Crystal A.

[0038] In some embodiments of the present disclosure, the crystalline A of the compound of formula (IV) has diffraction peaks at the following 2θ angles in its X-ray powder diffraction pattern using Cu Kα radiation: 16.82±0.20°, 17.61±0.20°, 19.31±0.20°.

[0039] In some embodiments of the present disclosure, the crystalline A of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation having diffraction peaks at the following 2θ angles: 16.82±0.20°, 17.61±0.20°, 19.31±0.20°, 20.53±0.20°, and 24.35±0.20°.

[0040] In some embodiments of the present disclosure, the crystalline A of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation, expressed as 2θ angle, and comprises at least 6, 7 or 8 diffraction peaks selected from the following: 16.82±0.20°, 17.61±0.20°, 18.31±0.20°, 19.31±0.20°, 20.53±0.20°, 21.46±0.20°, 22.35±0.20°, and 24.35±0.20°.

[0041] In some embodiments of the present disclosure, the crystalline A of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation having diffraction peaks at the following 2θ angles: 16.82±0.20°, 17.61±0.20°, 18.31±0.20°, 19.31±0.20°, 20.53±0.20°, 21.46±0.20°, 22.35±0.20°, 24.35±0.20°.

[0042] In some embodiments of the present disclosure, the crystal A of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation, expressed as 2θ angle, comprising at least 12, 13, 14, 15, 16, 17 or 18 diffraction peaks selected from the following: 12.14±0.20°, 16.82±0.20°, 17.61±0.20°, 18.31±0.20°, 18.64±0.20°, 19.31±0.20°, 20.26±0.20°, 21.80±0.20°, 22.50±0.20°, 23.30±0.20°, 24.70±0.20°, 25.90±0.20°, 26.80±0.20°, 27.80±0.20°, 28.60±0.20°, 29.80±0.20°, 30.80±0.20°, 31.30±0.20°, 32.80±0.20°, 33.30±0.20°, 34.70±0.20°, 35.80±0.20°, 36.80±0.20°, 37.80±0.20°, 38. .20°, 20.53±0.20°, 21.46±0.20°, 21.71±0.20°, 22.35±0.20°, 23.21±0.20°, 24.35±0.20°, 24.52±0.20°, 25.21±0.20°, 26.32±0.20°, 27.18±0.20°, 28.38±0.20°.

[0043] In some embodiments of the present disclosure, the crystalline A of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation having diffraction peaks at the following 2θ angles: 14.91±0.20°, 16.82±0.20°, 17.61±0.20°, 19.31±0.20°, 20.53±0.20°, 21.46±0.20°, 22.35±0.20°, 24.35±0.20°.

[0044] In some embodiments of the present disclosure, the crystalline A of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation having diffraction peaks at the following 2θ angles: 11.52±0.20°, 11.68±0.20°, 16.82±0.20°, 17.61±0.20°, 19.31±0.20°, 20.53±0.20°, 21.46±0.20°, 22.35±0.20°, 24.35±0.20°.

[0045] In some embodiments of the present disclosure, the crystalline A of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation having diffraction peaks at the following 2θ angles: 11.52±0.20°, 11.68±0.20°, 14.91±0.20°, 16.82±0.20°, 17.61±0.20°, 19.31±0.20°, 20.53±0.20°, 21.46±0.20°, 22.35±0.20°, 24.35±0.20°.

[0046] In some embodiments of the present disclosure, the crystalline A of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation having diffraction peaks at the following 2θ angles: 12.14±0.20°, 16.82±0.20°, 17.61±0.20°, 18.31±0.20°, 19.31±0.20°, 20.53±0.20°, 21.46±0.20°, 22.35±0.20°, 23.21±0.20°, 24.35±0.20°, 25.21±0.20°, 26.32±0.20°, 27.18±0.20°, 28.38±0.20°.

[0047] In some embodiments of the present disclosure, the crystal A of the compound of formula (IV) is prepared using Cu The X-ray powder diffraction pattern of Kα radiation has diffraction peaks at the following 2θ angles: 12.14±0.20°, 16.82±0.20°, 17.61±0.20°, 18.31±0.20°, 18.64±0.20°, 19.31±0.20°, 20.26±0.20°, 20.53±0.20°, 21.46±0.20°, 21.71±0.20°, 22.35±0.20°, 23.21±0.20°, 24.35±0.20°, 24.52±0.20°, 25.21±0.20°, 26.32±0.20°, 27.18±0.20°, 28.38±0.20°.

[0048] In some embodiments of the present disclosure, the crystalline A of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation having diffraction peaks at the following 2θ angles: 12.14°, 16.82°, 17.61°, 18.64°, 18.31°, 19.31°, 20.26°, 20.53°, 21.46°, 21.71°, 22.35°, 23.21°, 24.35°, 24.52°, 25.21°, 26.32°, 27.18°, 28.38°.

[0049] In some embodiments of the present disclosure, the crystalline A of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation, expressed as 2θ angle, comprising at least 16, 17, 18, 19 or 20 diffraction peaks selected from the following: 10.94±0.20°, 11.68±0.20°, 12.14±0.20°, 13.12±0.20°, 16.82±0.20°, 17.61±0.20°, 18.31±0.20°, 18.64±0.20°, 19.31±0.20°, 20.26±0.20°, 20.53±0.20°, 21.17±0.20°, 21.4 6±0.20°, 21.71±0.20°, 22.35±0.20°, 23.21±0.20°, 23.54±0.20°, 24.35±0.20°, 24.52±0.20°, 24.95±0.20°, 25.21±0.20°, 25.49±0.20°, 26.07±0.20°, 26.32±0.20°, 27.18±0.20°, 28.11±0.20°, 28.38±0.20°, 29.82±0.20°, 30.16±0.20°.

[0050] In some embodiments of the present disclosure, the crystalline A of the compound of formula (IV) has a diffraction peak at the following 2θ angles in its X-ray powder diffraction pattern using Cu Kα radiation: 10.94±0.20°, 11.68±0.20°, 12.14±0.20°, 13.12±0.20°, 16.82±0.20°, 17.61±0.20°, 18.31±0.20°, 18.64±0.20°, 19.31±0.20°, 20.26±0.20°, 20.53±0.20°, 21.17±0.20°, 21.46±0.20°, 21.7 1±0.20°, 22.35±0.20°, 23.21±0.20°, 23.54±0.20°, 24.35±0.20°, 24.52±0.20°, 24.95±0.20°, 25.21±0.20°, 25.49±0.20°, 26.07±0.20°, 26.32±0.20°, 27.18±0.20°, 28.11±0.20°, 28.38±0.20°, 29.82±0.20°, 30.16±0.20°.

[0051] In some embodiments of the present disclosure, the crystal A of the compound (IV) has a diffraction peak in an X-ray powder diffraction (XRPD) spectrum using Cu Kα radiation as shown in Table 1:

[0052] Table 1 XRPD spectrum analysis data of compound of formula (IV) crystal A

[0053]

[0054]

[0055] In some embodiments of the present disclosure, the crystalline A of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation as shown in Figure 1 shown.

[0056] In some embodiments of the present disclosure, the differential scanning calorimetry (DSC) curve of the crystal A of the compound of formula (IV) has an endothermic peak starting value at 147.29°C±3°C and an exothermic peak starting value at 177.45°C±3°C.

[0057] In some embodiments of the present disclosure, the differential scanning calorimetry (DSC) curve of the crystal A of the compound of formula (IV) has an endothermic peak at 150.18°C±3°C and an exothermic peak at 210.23°C±3°C.

[0058] In some embodiments of the present disclosure, the DSC spectrum of the crystal A of the compound of formula (IV) is as follows: Figure 2 shown.

[0059] In some embodiments of the present disclosure, the thermogravimetric analysis curve (TGA) of the crystal A of the compound of formula (IV) shows no obvious step weight loss.

[0060] In some embodiments of the present disclosure, the TGA spectrum of the crystal A of the compound of formula (IV) is as follows: Figure 3 shown.

[0061] In some embodiments of the present disclosure, the crystalline A of the compound of formula (IV) may exist in the form of a solvate crystal.

[0062] The present disclosure also provides a method for preparing the crystal A of the compound of formula (IV), comprising the step of stirring the crystal A of the compound of formula (IV) in a poor solvent, and further comprising a separation step.

[0063] In some embodiments of the present disclosure, the crystal A of the compound of formula (IV) of the present disclosure is prepared by the following method:

[0064] (a) adding the compound of formula (IV) into a benign solvent and dissolving it;

[0065] (b) slowly adding a poor solvent under stirring;

[0066] (c) precipitation of solids;

[0067] Wherein, the good solvent is tetrahydrofuran, and the poor solvent is n-heptane; the volume ratio of the good solvent to the poor solvent in the mixed solution is 1:1-20, preferably 1:1-11.

[0068] In some embodiments of the present disclosure, the crystal of the compound of formula (IV) is Crystal B.

[0069] In some embodiments of the present disclosure, the crystalline B of the compound of formula (IV) has diffraction peaks at the following 2θ angles in its X-ray powder diffraction pattern using Cu Kα radiation: 16.92±0.20°, 19.40±0.20°, 24.38±0.20°.

[0070] In some embodiments of the present disclosure, the crystalline B of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation having diffraction peaks at the following 2θ angles: 16.92±0.20°, 17.70±0.20°, 18.35±0.20°, 19.40±0.20°, and 24.38±0.20°.

[0071] In some embodiments of the present disclosure, the crystalline B of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation, expressed as 2θ angle, and comprises at least 6, 7, 8 or 9 diffraction peaks selected from the following: 14.20±0.20°, 16.92±0.20°, 17.70±0.20°, 18.35±0.20°, 19.40±0.20°, 20.42±0.20°, 21.50±0.20°, 22.37±0.20°, and 24.38±0.20°.

[0072] In some embodiments of the present disclosure, the crystalline B of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation having diffraction peaks at the following 2θ angles: 14.20±0.20°, 16.92±0.20°, 17.70±0.20°, 18.35±0.20°, 19.40±0.20°, 24.38±0.20°.

[0073] In some embodiments of the present disclosure, the crystalline B of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation having diffraction peaks at the following 2θ angles: 14.20±0.20°, 16.92±0.20°, 17.70±0.20°, 18.35±0.20°, 19.40±0.20°, 20.42±0.20°, 21.50±0.20°, 22.37±0.20°, 24.38±0.20°.

[0074] In some embodiments of the present disclosure, the crystalline B of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation, expressed as 2θ angle, and comprises at least 8, 9, 10 or 11 diffraction peaks selected from the following: 14.20±0.20°, 16.92±0.20°, 17.70±0.20°, 18.35±0.20°, 19.40±0.20°, 20.42±0.20°, 21.50±0.20°, 22.37±0.20°, 24.38±0.20°, 26.58±0.20°, and 27.23±0.20°.

[0075] In some embodiments of the present disclosure, the crystalline B of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation having diffraction peaks at the following 2θ angles: 14.20±0.20°, 16.92±0.20°, 17.70±0.20°, 18.35±0.20°, 19.40±0.20°, 20.42±0.20°, 21.50±0.20°, 22.37±0.20°, 24.38±0.20°, 26.58±0.20°, 27.23±0.20°.

[0076] In some embodiments of the present disclosure, the crystal B of the compound of formula (IV) is prepared using Cu The X-ray powder diffraction pattern of Kα radiation has diffraction peaks at the following 2θ angles: 13.21±0.20°, 14.20±0.20°, 16.92±0.20°, 17.70±0.20°, 17.92±0.20°, 18.35±0.20°, 18.66±0.20°, 19.40±0.20°, 20.42±0.20°, 20.57±0.20°, 21.50±0.20°, 22.37±0.20°, 23.26±0.20°, 24.38±0.20°, 26.21±0.20°, 26.58±0.20°, 27.23±0.20°, 33.91±0.20°.

[0077] In some embodiments of the present disclosure, the crystalline B of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation having diffraction peaks at the following 2θ angles: 13.21°, 14.20°, 16.92°, 17.70°, 17.92°, 18.35°, 18.66°, 19.40°, 20.42°, 20.57°, 21.50°, 22.37°, 23.26°, 24.38°, 26.21°, 26.58°, 27.23°, and 33.91°.

[0078] In some embodiments of the present disclosure, the crystal B of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation, expressed as 2θ angle, comprising at least 16, 17, 18, 19 or 20 diffraction peaks selected from the following: 13.21±0.20°, 14.20±0.20°, 16.92±0.20°, 17.70±0.20°, 17.92±0.20°, 18.35±0.20°, 18.66±0.20°, 19.40±0.20°. °, 20.42±0.20°, 20.57±0.20°, 21.50±0.20°, 22.37±0.20°, 23.26±0.20°, 23.42±0.20°, 24.38±0.20°, 26.21±0.20°, 26.58±0.20°, 27.23±0.20°, 32.10±0.20°, 33.91±0.20°.

[0079] In some embodiments of the present disclosure, the crystalline B of the compound of formula (IV) has a diffraction peak at the following 2θ angles in its X-ray powder diffraction pattern using Cu Kα radiation: 13.21±0.20°, 14.20±0.20°, 16.92±0.20°, 17.70±0.20°, 17.92±0.20°, 18.35±0.20°, 18.66±0.20°, 19.40±0.20°, 20.42±0.20°. °, 20.57±0.20°, 21.50±0.20°, 22.37±0.20°, 23.26±0.20°, 23.42±0.20°, 24.38±0.20°, 26.21±0.20°, 26.58±0.20°, 27.23±0.20°, 32.10±0.20°, 33.91±0.20°.

[0080] In some embodiments of the present disclosure, the XRPD pattern analysis data of the crystal B is shown in Table 2:

[0081] Table 2 XRPD spectrum analysis data of compound of formula (IV) crystal B

[0082]

[0083] In some embodiments of the present disclosure, the crystal B of the compound of formula (IV) has an XRPD pattern using Cu Kα radiation as shown in Figure 4 shown.

[0084] In some embodiments of the present disclosure, the differential scanning calorimetry (DSC) curve of the crystal B of the compound of formula (IV) has an endothermic peak starting value at 142.02°C±3°C and an exothermic peak starting value at 177.72°C±3°C.

[0085] In some embodiments of the present disclosure, the differential scanning calorimetry (DSC) curve of the crystal B of the compound of formula (IV) has an endothermic peak at 150.24°C±3°C and an exothermic peak at 209.69°C±3°C, respectively.

[0086] In some embodiments of the present disclosure, the DSC spectrum of the crystal B of the compound of formula (IV) is as follows Figure 5 shown.

[0087] In some embodiments of the present disclosure, the thermogravimetric analysis curve of the crystal B of the compound of formula (IV) shows no obvious step weight loss.

[0088] In some embodiments of the present disclosure, the TGA spectrum of the crystal B of the compound of formula (IV) is as follows Figure 6 shown.

[0089] In some embodiments of the present disclosure, the crystalline B of the compound of formula (IV) may exist in the form of a solvate crystal.

[0090] Crystal B In some embodiments of the present disclosure, Crystal B of the compound of formula (IV) of the present disclosure is prepared by the following method:

[0091] (a) adding the compound of formula (IV) into a benign solvent and dissolving it;

[0092] (b) slowly adding a poor solvent under stirring;

[0093] (c) precipitation of solids;

[0094] Wherein, the good solvent is acetone, the poor solvent is n-heptane, and the volume ratio of the good solvent to the poor solvent in the mixed solution is 1:1-10, preferably 1:5.

[0095] In some embodiments of the present disclosure, the crystal of the compound of formula (IV) is Crystal C.

[0096] In some embodiments of the present disclosure, the crystalline C of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation with diffraction peaks at the following 2θ angles: 12.38±0.20°, 14.23±0.20°, 17.93±0.20°, and 20.44±0.20°.

[0097] In some embodiments of the present disclosure, the crystalline C of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation having diffraction peaks at the following 2θ angles: 10.01±0.20°, 12.38±0.20°, 14.23±0.20°, 17.93±0.20°, and 20.44±0.20°.

[0098] In some embodiments of the present disclosure, the crystalline C of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation having diffraction peaks at the following 2θ angles: 7.14±0.20°, 10.01±0.20°, 12.38±0.20°, 14.23±0.20°, 17.93±0.20°, 20.44±0.20°.

[0099] In some embodiments of the present disclosure, the crystalline C of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation, expressed as 2θ angle, and comprises at least 6, 7, 8 or 9 diffraction peaks selected from the following: 12.38±0.20°, 14.23±0.20°, 16.88±0.20°, 17.93±0.20°, 20.11±0.20°, 20.44±0.20°, 20.86±0.20°, 21.38±0.20°, and 26.62±0.20°.

[0100] In some embodiments of the present disclosure, the crystalline C of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation having diffraction peaks at the following 2θ angles: 12.38±0.20°, 14.23±0.20°, 16.88±0.20°, 17.93±0.20°, 20.44±0.20°, and 26.62±0.20°.

[0101] In some embodiments of the present disclosure, the crystalline C of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation having diffraction peaks at the following 2θ angles: 12.38±0.20°, 14.23±0.20°, 16.88±0.20°, 17.93±0.20°, 20.44±0.20°, 20.86±0.20°, 21.38±0.20°, 26.62±0.20°.

[0102] In some embodiments of the present disclosure, the crystalline C of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation, expressed as 2θ angle, and comprises at least 9, 10, 11 or 12 diffraction peaks selected from the following: 12.38±0.20°, 13.07±0.20°, 14.23±0.20°, 16.88±0.20°, 17.93±0.20°, 20.11±0.20°, 20.44±0.20°, 20.86±0.20°, 21.09±0.20°, 21.38±0.20°, 22.57±0.20°, 26.22±0.20°, 26.62±0.20°.

[0103] In some embodiments of the present disclosure, the crystalline C of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation having diffraction peaks at the following 2θ angles: 12.38±0.20°, 13.07±0.20°, 14.23±0.20°, 16.88±0.20°, 17.93±0.20°, 20.44±0.20°, 20.86±0.20°, 21.09±0.20°, 21.38±0.20°, 22.57±0.20°, 26.22±0.20°, 26.62±0.20°.

[0104] In some embodiments of the present disclosure, the crystalline C of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation, expressed as 2θ angle, and comprises at least 9, 10, 11 or 12 diffraction peaks selected from the following: 7.14±0.20°, 8.12±0.20°, 10.01±0.20°, 12.38±0.20°, 14.23±0.20°, 16.88±0.20°, 17.93±0.20°, 20.11±0.20°, 20.44±0.20°, 20.86±0.20°, 21.38±0.20°, and 26.62±0.20°.

[0105] In some embodiments of the present disclosure, the crystalline C of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation having diffraction peaks at the following 2θ angles: 7.14±0.20°, 8.12±0.20°, 10.01±0.20°, 12.38±0.20°, 14.23±0.20°, 16.88±0.20°, 17.93±0.20°, 20.11±0.20°, 20.44±0.20°, 20.86±0.20°, 21.38±0.20°, 26.62±0.20°.

[0106] In some embodiments of the present disclosure, the crystalline C of the compound of formula (IV) has a diffraction peak at the following 2θ angles in its X-ray powder diffraction pattern using Cu Kα radiation: 10.01±0.20°, 12.38±0.20°, 13.07±0.20°, 13.50±0.20°, 13.98±0.20°, 14.23±0.20°, 16.88±0.20°, 17.93±0.20°, 20.1 1±0.20°, 20.44±0.20°, 20.86±0.20°, 21.09±0.20°, 21.38±0.20°, 22.57±0.20°, 23.46±0.20°, 25.89±0.20°, 26.22±0.20°, 26.62±0.20°, 27.13±0.20°.

[0107] In some embodiments of the present disclosure, the crystalline C of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation having diffraction peaks at the following 2θ angles: 10.01°, 12.38°, 13.07°, 13.50°, 13.98°, 14.23°, 16.88°, 17.93°, 20.11°, 20.44°, 20.86°, 21.09°, 21.38°, 22.57°, 23.46°, 25.89°, 26.22°, 26.62°, 27.13°.

[0108] In some embodiments of the present disclosure, the crystalline C of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation, expressed as 2θ angle, comprising at least 16, 17, 18, 19 or 20 diffraction peaks selected from the following: 7.14±0.20°, 8.12±0.20°, 10.01±0.20°, 12.38±0.20°, 13.07±0.20°, 13.50±0.20°, 13.98±0.20°, 14.23±0.20°, 15.71±0.20°, 16.88 ±0.20°, 17.93±0.20°, 19.40±0.20°, 20.11±0.20°, 20.44±0.20°, 20.86±0.20°, 21.09±0.20°, 21.38±0.20°, 22.57±0.20°, 23.46±0.20°, 25.89±0.20°, 26.22±0.20°, 26.62±0.20°, 27.13±0.20°.

[0109] In some embodiments of the present disclosure, the crystalline C of the compound of formula (IV) has an X-ray powder diffraction pattern using Cu Kα radiation at the following 2θ angles: 7.14±0.20°, 8.12±0.20°, 10.01±0.20°, 12.38±0.20°, 13.07±0.20°, 13.50±0.20°, 13.98±0.20°, 14.23±0.20°, 15.71±0.20°, 16.88±0.20°, 17.93 ±0.20°, 19.40±0.20°, 20.11±0.20°, 20.44±0.20°, 20.86±0.20°, 21.09±0.20°, 21.38±0.20°, 22.57±0.20°, 23.46±0.20°, 25.89±0.20°, 26.22±0.20°, 26.62±0.20°, 27.13±0.20°.

[0110] In some embodiments of the present invention, the XRPD pattern analysis data of the crystal C is shown in Table 3:

[0111] Table 3 XRPD spectrum analysis data of compound C of formula (IV)

[0112]

[0113] In some embodiments of the present disclosure, the crystalline C of the compound of formula (IV) has an XRPD pattern as shown in Figure 7 shown.

[0114] In some embodiments of the present disclosure, the differential scanning calorimetry (DSC) curve of the crystal C of the compound of formula (IV) has an endothermic peak starting value at 142.30°C±3°C and an exothermic peak starting value at 176.16°C±3°C, respectively.

[0115] In some embodiments of the present disclosure, the differential scanning calorimetry (DSC) curve of the crystal C of the compound of formula (IV) has an endothermic peak at 145.14°C±3°C and an exothermic peak at 209.48°C±3°C, respectively.

[0116] In some embodiments of the present disclosure, the DSC spectrum of the crystal C of the compound of formula (IV) is as follows Figure 8 shown.

[0117] In some embodiments of the present disclosure, the thermogravimetric analysis curve (TGA) of the crystal C of the compound of formula (IV) shows no obvious step weight loss.

[0118] In some embodiments of the present disclosure, the TGA spectrum of the crystal C of the compound of formula (IV) is as follows Fig. 9 shown.

[0119] In some embodiments of the present disclosure, the crystalline C of the compound of formula (IV) may exist in the form of a solvate crystal.

[0120] The present disclosure also provides a method for preparing the crystalline C of the compound of formula (IV), which comprises:

[0121] (a) adding the compound of formula (IV) into a benign solvent and dissolving it;

[0122] (b) slowly adding a poor solvent under stirring;

[0123] (c) precipitation of solids;

[0124] Wherein, the good solvent is tetrahydrofuran, the poor solvent is water, and the volume ratio of the good solvent to the poor solvent in the mixed solution is 1:1-50, preferably 1:10.

[0125] In some embodiments of the present disclosure, the amorphous XRPD pattern of the compound of formula (IV) is as follows: Fig.10 shown.

[0126] In another aspect, the present disclosure provides a crystal of a compound of formula (II):

[0127]

[0128] In another aspect, the present disclosure provides a method for preparing the crystal of the compound of formula (II), comprising the step of precipitating the crystal of the compound of formula (II) in a solvent.

[0129] In another aspect, the present disclosure provides a crystal of a compound of formula (III):

[0130]

[0131] In another aspect, the present disclosure provides a method for preparing the crystal of the compound of formula (III), comprising the step of precipitating the crystal of the compound of formula (III) in a solvent.

[0132] In another aspect, the present disclosure provides a crystal of a compound of formula (V):

[0133]

[0134] In another aspect, the present disclosure provides a method for preparing the crystal of the compound of formula (V), comprising the step of precipitating the crystal of the compound of formula (V) in a solvent.

[0135] In another aspect, the present disclosure provides a crystal of a compound of formula (VI):

[0136]

[0137] In another aspect, the present disclosure provides a method for preparing the crystal of the compound of formula (VI), comprising the step of precipitating the crystal of the compound of formula (VI) in a solvent.

[0138] On the other hand, the present disclosure provides a crystalline composition comprising crystals of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the crystals account for more than 50% by weight of the crystalline composition, preferably more than 80%, more preferably more than 90%, and most preferably more than 95%.

[0139] In another aspect, the present disclosure provides a pharmaceutical composition, comprising a therapeutically effective amount of a crystal of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or the crystalline composition.

[0140] In another aspect, the present disclosure provides a method for treating a disease, comprising administering to an individual in need thereof a therapeutically effective amount of a crystal of the compound of formula (I) or a pharmaceutically acceptable salt thereof, or the crystal composition, or the pharmaceutical composition.

[0141] In another aspect, the present disclosure provides a crystal of the compound of formula (I) or a pharmaceutically acceptable salt thereof, or a crystal composition, or a use of the pharmaceutical composition in preparing a drug for treating a disease.

[0142] In yet another aspect, the present disclosure provides use of the crystal of the compound of formula (I) or a pharmaceutically acceptable salt thereof, or the crystal composition, or the pharmaceutical composition in treating IgA nephropathy.

[0143] In some embodiments of the present disclosure, in the crystalline composition, pharmaceutical composition, method for treating a disease, use in preparing a medicament for treating a disease, and use in treating a disease described in the present disclosure, the crystals of the compound of formula (I) or a pharmaceutically acceptable salt thereof are selected from the group consisting of the crystals of the compound of formula (II), the compound of formula (III), the compound of formula (IV), the compound of formula (V), the compound of formula (VI), or the crystals of a pharmaceutically acceptable salt thereof; or, the crystals of the compound of formula (I) or a pharmaceutically acceptable salt thereof are selected from the group consisting of the crystals of the compound of formula (II), the crystals of the compound of formula (III), the crystals of the compound of formula (IV), the crystals of the compound of formula (V), or the crystals of the compound of formula (VI).

[0144] In some embodiments of the present disclosure, in the crystalline composition, pharmaceutical composition, method for treating IgA nephropathy, use in preparing a medicament for treating IgA nephropathy, and use in treating a disease described in the present disclosure, the crystal of the compound of formula (IV) is selected from Crystal A, Crystal B or Crystal C of the compound of formula (IV).

[0145] In yet another aspect, the present disclosure provides an amorphous form of the compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0146] In another aspect, the present disclosure provides a pharmaceutical composition comprising a therapeutically effective amount of an amorphous form of the compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0147] In another aspect, the present disclosure provides a method for treating a disease, comprising administering to an individual in need thereof a therapeutically effective amount of the amorphous form of the compound of formula (I) or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition.

[0148] In another aspect, the present disclosure provides use of the amorphous form of the compound of formula (I) or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition in the preparation of a medicament for treating a disease.

[0149] In another aspect, the present disclosure provides the use of the amorphous form of the compound of formula (I) or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition in treating a disease.

[0150] In some other embodiments of the present disclosure, the amorphous form of the compound of formula (I) or its pharmaceutically acceptable salt is selected from the compound of formula (II), the compound of formula (III), the compound of formula (IV), the compound of formula (V), the compound of formula (VI), or the amorphous form of their pharmaceutically acceptable salts; or, the amorphous form of the compound of formula (I) or its pharmaceutically acceptable salt is selected from the amorphous form of the compound of formula (II), the amorphous form of the compound of formula (III), the amorphous form of the compound of formula (IV), the amorphous form of the compound of formula (V), or the amorphous form of the compound of formula (VI).

[0151] In some other embodiments of the present disclosure, the amorphous form of the compound of formula (VI) has an XRPD pattern as shown in Fig.10 shown.

[0152] In another aspect; alternatively, containing a single dose of 0.1 to 600 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0153] In another aspect, the present disclosure provides a pharmaceutical composition of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition is prepared as a single dose of 0.001 to 10000 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof; or, a single dose of 0.01 to 2000 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof; or, a single dose of 0.02 to 800 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof; or, a single dose of 0.1 to 600 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0154] In another aspect, the present disclosure provides a method for treating a disease, the method comprising administering to an individual in need thereof a pharmaceutical composition of a compound of formula (I) or a pharmaceutically acceptable salt thereof at a daily dose of 0.001 to 180 mg / kg body weight; or, administering to an individual in need thereof a pharmaceutical composition of a compound of formula (I) or a pharmaceutically acceptable salt thereof at a daily dose of 0.002 to 20 mg / kg body weight; or, administering to an individual in need thereof a pharmaceutical composition of 0.001 to 10000 mg per day; or, administering to an individual in need thereof a pharmaceutical composition of 0.01 to 2000 mg per day; or, administering to an individual in need thereof a pharmaceutical composition of 0.02 to 800 mg per day; or, administering to an individual in need thereof a pharmaceutical composition of 0.1 to 600 mg per day.

[0155] In another aspect, the present disclosure provides a use of a pharmaceutical composition of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a disease, wherein the pharmaceutical composition is prepared as a pharmaceutical composition of a single dose of 0.001 to 10000 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof; or, a pharmaceutical composition of a single dose of 0.01 to 2000 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof; or, a pharmaceutical composition of a single dose of 0.02 to 800 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof; or, a pharmaceutical composition of a single dose of 0.1 to 600 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0156] In another aspect, the present disclosure provides use of a pharmaceutical composition of a compound of formula (I) or a pharmaceutically acceptable salt thereof in treating a disease, wherein the pharmaceutical composition contains a single dose of 0.001 to 10,000 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof; or, a single dose of 0.01 to 2,000 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof; or, a single dose of 0.02 to 800 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof; or, a single dose of 0.1 to 600 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0157] In some other embodiments of the present disclosure, the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from a compound of formula (II), a compound of formula (III), a compound of formula (IV), a compound of formula (V), a compound of formula (VI), or a pharmaceutically acceptable salt thereof; or, each of them is crystalline or amorphous.

[0158] In some other embodiments of the present disclosure, the pharmaceutical composition of the compound of formula (I) or a pharmaceutically acceptable salt thereof is a pharmaceutical composition for treating a disease.

[0159] In some embodiments of the present disclosure, the pharmaceutical composition described in the present disclosure may or may not contain pharmaceutically acceptable excipients.

[0160] In some embodiments of the present disclosure, the pharmaceutical compositions described herein may further include one or more other therapeutic agents.

[0161] In some embodiments of the present disclosure, the disease described in the present disclosure is selected from ETA receptor-related diseases.

[0162] In some embodiments of the present disclosure, the disease described herein is selected from IgA nephropathy.

[0163] Technical Effects

[0164] The compounds disclosed herein all exhibited effects on human ET A The in vitro antagonism of the receptor is extremely active, with good in vivo efficacy, and the disclosed compounds have good exposure and bioavailability, and can alleviate renal injury in rats, have good PK properties and oral absorption rate, and may provide more effective treatment for renal injury and renal fibrosis caused by excessive activation of renal ETA receptors, FSGS, and IgA nephropathy. In addition, the crystal preparation of the disclosed compounds is simple, and at least in one or more aspects of pharmacokinetics, bioavailability, low hygroscopicity, fluidity, high stability (e.g., no crystallization or chemical stability under high temperature, high humidity, strong light conditions), solubility, purity or mass uniformity, etc., it has excellent properties (e.g., can be proved by the test method of the experimental example disclosed in the present invention), and is suitable for use as a drug.

[0165] Definition and Description

[0166] Unless otherwise specified, the following terms and phrases used herein are intended to have the following meanings. A particular phrase or term should not be considered to be uncertain or unclear in the absence of a special definition, but should be understood according to its ordinary meaning. When a trade name appears in this article, it is intended to refer to its corresponding commercial product or its active ingredient.

[0167] For any given crystalline form, the relative intensity of the diffraction peaks can change due to the preferred orientation caused by factors such as crystal morphology, which is well known in the field of crystallography. Where there is a preferred orientation effect, the peak intensity changes, but the diffraction peak position of the crystal form cannot be changed. In addition, for any given crystal form, there may be a slight error in the position of the peak, which is also well known in the field of crystallography. For example, due to changes in temperature when analyzing a sample, movement of the sample, or calibration of the instrument, the position of the peak can move, and the measurement error of the 2θ value is sometimes about ± 0.20 degrees. Therefore, it is well known to those skilled in the art that this error should be taken into account when determining each crystalline structure.

[0168] DSC measures the transition temperature when a crystal absorbs or releases heat due to changes in its crystalline structure or melting of the crystal. For the same type of crystal form of the same compound, in consecutive analyses, the error of thermal transition temperature and melting point is typically within about 5°C or 3°C. When we say that a compound has a given DSC peak or melting point, this refers to the DSC peak or melting point ±5°C or ±3°C. DSC provides an auxiliary method for distinguishing different crystal forms. Different crystalline forms can be identified based on their different transition temperature characteristics. It should be pointed out that for mixtures, their DSC peaks or melting points may vary over a larger range. In addition, since decomposition is accompanied by the melting of the substance, the melting temperature is related to the heating rate.

[0169] For the same crystal form, the TGA weight loss temperature may vary due to factors such as the measuring instrument, measuring method / conditions, etc. For any specific crystal form, the weight loss temperature may have an error of about ±5°C or about ±3°C.

[0170] It should be noted that when preparing drug crystal forms, during the contact between drug molecules and solvent molecules, it is difficult to avoid the situation that the solvent molecules and compound molecules form a co-crystal and remain in the solid material due to external conditions and internal factors, thereby forming a solvate, specifically including a stoichiometric solvate and a non-stoichiometric solvate. The solvates are all included in the scope of the present invention.

[0171] The "pharmaceutically acceptable excipients" refer to inert substances that are administered together with the active ingredients and are conducive to the administration of the active ingredients, including but not limited to any glidants, sweeteners, diluents, preservatives, dyes / colorants, flavor enhancers, surfactants, wetting agents, dispersants, disintegrants, suspending agents, stabilizers, isotonic agents, solvents or emulsifiers that are acceptable for use in humans or animals (such as livestock) and approved by the State Food and Drug Administration.

[0172] The term "crystalline composition" refers to a mixture of a crystal of a compound of formula (I) or (II) or (III) or (IV) or (V) or (VI) of the present disclosure and other crystalline forms or amorphous forms or other impurities of the compound. For example, the crystalline composition of Crystal A of the compound of formula (IV) contains other crystalline forms or amorphous forms or other impurities of the compound of formula (IV) in addition to Crystal A of the compound of formula (IV).

[0173] The term "pharmaceutical composition" refers to a mixture of one or more compounds of the present disclosure or their salts and a pharmaceutically acceptable excipient. The purpose of a pharmaceutical composition is to facilitate administration of the compounds of the present disclosure to an organism.

[0174] The pharmaceutical compositions of the present disclosure can be prepared by combining the compounds of the present disclosure with suitable pharmaceutically acceptable excipients, for example, they can be formulated into solid, semi-solid, liquid or gaseous preparations, such as tablets, pills, capsules, powders, granules, ointments, emulsions, suspensions, suppositories, injections, inhalants, gels, microspheres and aerosols, etc.

[0175] Typical routes of administration of the disclosed compounds or pharmaceutically acceptable salts thereof or pharmaceutical compositions thereof include, but are not limited to, oral, rectal, topical, inhalation, parenteral, sublingual, intravaginal, intranasal, intraocular, intraperitoneal, intramuscular, subcutaneous, intravenous administration.

[0176] The pharmaceutical composition of the present disclosure can be manufactured by methods well known in the art, such as conventional mixing methods, dissolving methods, granulating methods, making dragees, grinding methods, emulsifying methods, freeze-drying methods, and the like.

[0177] In some embodiments, the pharmaceutical composition is in oral form. For oral administration, the pharmaceutical composition can be formulated by mixing the active compound with pharmaceutically acceptable excipients well known in the art. These excipients enable the compounds of the present disclosure to be formulated into tablets, pills, lozenges, dragees, capsules, gels, slurries, suspensions, etc., for oral administration to patients.

[0178] Solid oral compositions can be prepared by conventional mixing, filling or tableting methods. For example, they can be obtained by mixing the active compound with a solid excipient, optionally grinding the resulting mixture, adding other suitable excipients if necessary, and then processing the mixture into particles to obtain a tablet or dragee core. Suitable excipients include, but are not limited to, adhesives, diluents, disintegrants, lubricants, glidants, sweeteners or flavoring agents, etc.

[0179] The pharmaceutical composition may also be suitable for parenteral administration, such as sterile solutions, suspensions or lyophilized products in appropriate unit dosage forms.

[0180] In all administration methods of the disclosed compound of formula (I), the daily dosage is 0.001 to 200 mg / kg body weight, for example, a single dose of 0.001 to 10000 mg of the pharmaceutical composition of the compound of formula (I) can be administered, preferably a single dose of 0.01 to 2000 mg of the pharmaceutical composition of the compound of formula (I). The disclosed compound can be prepared by a variety of synthesis methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent substitution methods well known to those skilled in the art, and preferred embodiments include but are not limited to the embodiments disclosed herein.

[0181] The therapeutic dosage of the disclosed compounds may be determined, for example, based on the specific use of the treatment, the manner in which the compound is administered, the patient's health and condition, and the judgment of the prescribing physician. The ratio or concentration of the disclosed compounds in a pharmaceutical composition may not be fixed, depending on a variety of factors, including dosage, chemical properties (e.g., hydrophobicity), and route of administration.

[0182] The term "treatment" means administering the compounds or formulations described herein to improve or eliminate a disease or one or more symptoms associated with the disease, and includes:

[0183] (i) inhibiting a disease or disease state, i.e. arresting its development;

[0184] (ii) ameliorating a disease or condition, even if causing regression of the disease or condition.

[0185] The term "therapeutically effective amount" means an amount of a compound of the present disclosure that (i) treats a particular disease, condition, or disorder, (ii) alleviates, ameliorates, or eliminates one or more symptoms of a particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of a particular disease, condition, or disorder described herein. The amount of a compound of the present disclosure that constitutes a "therapeutically effective amount" varies depending on the compound, the disease state and its severity, the mode of administration, and the age of the mammal to be treated, but can be routinely determined by one skilled in the art based on their own knowledge and the present disclosure.

[0186] Unless otherwise required in the present disclosure, throughout the specification and the claims that follow, the word "comprise" and its English variations such as "comprises" and "comprising" should be interpreted in an open, inclusive sense, i.e., "including but not limited to."

[0187] References to "one embodiment" or "an embodiment" or "in another embodiment" or "in certain embodiments" throughout this specification are intended to include in at least one embodiment the specific referenced elements, structures or features described in connection with that embodiment. Thus, the phrases "in one embodiment" or "in an embodiment" or "in another embodiment" or "in certain embodiments" appearing in different places throughout the specification do not necessarily all refer to the same embodiment. Furthermore, the specific elements, structures or features may be combined in any appropriate manner in one or more embodiments.

[0188] It should be understood that the singular article "a", "an", and "the" as used in this disclosure and the appended claims includes plural referents unless the context clearly dictates otherwise. Thus, for example, a reference to a reaction including "a catalyst" includes one catalyst, or two or more catalysts. It should also be understood that the term "or" is generally used in its sense including "and / or" unless the context clearly dictates otherwise.

[0189] The term "single dose" or "unit preparation" refers to the smallest packaging unit of a drug containing a certain amount of active ingredient. For example, if a box of medicine contains seven capsules, each capsule is a single dose or unit preparation; for example, if a box of medicine contains seven tablets, each tablet is a single dose unit preparation.

[0190] The intermediate compounds disclosed herein can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent substitutions well known to those skilled in the art. Preferred embodiments include but are not limited to the examples disclosed herein.

[0191] The chemical reactions of the specific embodiments of the present disclosure are carried out in a suitable solvent, which must be suitable for the chemical changes of the present disclosure and the reagents and materials required. In order to obtain the compounds of the present disclosure, it is sometimes necessary for those skilled in the art to modify or select the synthesis steps or reaction processes based on the existing embodiments.

[0192] The structure of the compounds disclosed herein can be confirmed by conventional methods known to those skilled in the art. If the disclosure involves the absolute configuration of the compound, the absolute configuration can be confirmed by conventional technical means in the art. For example, single crystal X-ray diffraction (SXRD) is used to collect diffraction intensity data of the cultured single crystal using a Bruker D8 venture diffractometer, with the light source being CuKα radiation and the scanning mode being: After scanning and collecting relevant data, the crystal structure is further analyzed using the direct method (Shelxs97) to confirm the absolute configuration.

[0193] The present disclosure will be described in detail below through examples, which are not intended to limit the present disclosure in any way.

[0194] The solvents used in the present disclosure are commercially available and used without further purification.

[0195] The solvents used in the present disclosure can be obtained commercially. The present disclosure uses the following abbreviations: HPLC stands for high performance liquid chromatography; °C stands for degrees Celsius; h stands for hour; mL stands for milliliter; mM stands for millimole per liter; mmol stands for millimole; μmol stands for micromole; 1 H NMR stands for proton nuclear magnetic resonance; MS stands for mass spectrometry; min stands for minute; pH stands for negative logarithm of the molar concentration of hydrogen ion; DMSO stands for dimethyl sulfoxide.

[0196] The compounds are named by conventional naming methods in the art or The software names were used, and commercially available compounds were named using the supplier's catalog names.

[0197] The present invention discloses a powder X-ray diffractometer (XRPD) method

[0198] Instrument model: Bruker D2 PHASER X-ray diffractometer

[0199] Test method: About 10-20 mg of sample was used for XRPD detection.

[0200] The detailed XRPD parameters are as follows:

[0201] Light pipe: Cu, kα,

[0202] Light tube voltage: 30kV, light tube current: 10mA

[0203] Divergence slit: 0.60mm

[0204] Detector slit: 0.075mm

[0205] Anti-scatter slit: 0mm

[0206] Scanning range: 3-40 degrees

[0207] Step diameter: 0.02deg

[0208] Step length: 0.2 seconds

[0209] The present invention discloses a differential scanning calorimeter (DSC) method

[0210] Instrument model: DSC 250 differential scanning calorimeter

[0211] Test method: Take a sample (~2 mg) and place it in a DSC aluminum pan for testing. Under 50 mL / min N2 conditions, heat the sample from 25°C (room temperature) to 250°C at a heating rate of 10°C / min.

[0212] Thermogravimetric analysis (TGA) method disclosed herein

[0213] Instrument model: TGA500 thermogravimetric analyzer

[0214] Test method: Take a sample (2-5 mg) and place it in a TGA platinum pan for testing. Under 25 mL / min N2 conditions, heat the sample from room temperature to 300°C or 20% weight loss at a heating rate of 10°C / min.

[0215] The present invention discloses a dynamic vapor sorption analysis (DVS) method

[0216] Instrument model: SMSDVS Advantage Dynamic Vapor Sorption Instrument

[0217] Test conditions: Take a sample (10-15 mg) and place it in the DVS sample tray for testing.

[0218] The detailed DVS parameters are as follows:

[0219] Temperature: 25℃

[0220] Balance: dm / dt = 0.01% / min (minimum: 10min, maximum: 180min)

[0221] Drying: Drying at 0% RH for 120 minutes

[0222] RH(%) test level: 10%

[0223] RH(%) test step range: 0%-90%-0%

[0224] The moisture absorption evaluation is classified as follows:

[0225] Hygroscopicity classification ΔW% deliquescence Absorbs enough water to form a liquid Highly hygroscopic ΔW%≥15% Hygroscopic 15%>ΔW%≥2% Slightly hygroscopic 2%>ΔW%≥0.2% No or almost no hygroscopicity ΔW%<0.2%

[0226] Note: ΔW% indicates the weight gain of the test sample at 25±1℃ and 80±2%RH. BRIEF DESCRIPTION OF THE DRAWINGS

[0227] Figure 1 is the Cu-Kα radiation XRPD spectrum of compound (IV) crystal A;

[0228] Figure 2 is the DSC spectrum of (IV) compound crystal A;

[0229] Figure 3 is the TGA spectrum of (IV) compound crystal A;

[0230] Figure 4 is the Cu-Kα radiation XRPD spectrum of compound (IV) crystal B;

[0231] Figure 5 is the DSC spectrum of (IV) compound crystal B;

[0232] Figure 6 is the TGA spectrum of (IV) compound crystal B;

[0233] Figure 7 is the Cu-Kα radiation XRPD spectrum of crystal C of compound (IV);

[0234] Figure 8 is the DSC spectrum of (IV) compound crystal C;

[0235] Fig. 9 This is the TGA spectrum of compound (IV) crystal C;

[0236] Fig.10 This is the XRPD spectrum of the amorphous form of compound (IV) using Cu-Kα radiation. DETAILED DESCRIPTION

[0237] In order to better understand the content of the present invention, further description is given below in conjunction with specific embodiments, but the specific implementation methods are not intended to limit the content of the present invention.

[0238] Example 1: Preparation of the compound of formula (II)

[0239]

[0240] Step 1: Synthesis of compound b

[0241] At room temperature and under the protection of nitrogen, cyclopropanesulfonamide (318.41 mg) was dissolved in dimethyl sulfoxide (15 mL), potassium tert-butoxide (491.48 mg) was added thereto at 25 ° C, and compound a (500.00 mg) was slowly added thereto after stirring for 30 minutes, and stirred at room temperature for 15 hours after the addition. After the reaction was completed, water (100 mL) was added for dilution, 2M dilute hydrochloric acid was used to adjust the pH to 6, ethyl acetate (200 mL × 3) was extracted, and the organic phases were combined. The organic phase was washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The crude product was separated by column chromatography (eluent: dichloromethane / methanol = 100 / 1-30 / 1, volume ratio) to obtain compound b. 1 H NMR(400MHz, CDCl3)δ:8.60(s,1H),7.84(s,1H),3.46-3.17(m,1H),1.53-1.44(m,2H),1.21-1.14(m,2H)

[0242] Step 2: Synthesis of compound c

[0243] At room temperature and under nitrogen protection, potassium tert-butoxide (2.30 g) was added to ethylene glycol (42.58 g), the reaction system was heated to 40 ° C and stirred for 30 minutes, compound b (3.2 g) was added thereto, and the reaction system was heated to 90 ° C and stirred for 18 hours. After the reaction was completed, the reaction system was cooled to room temperature, diluted with water (100 mL), 2M dilute hydrochloric acid was used to adjust the pH to 2, ethyl acetate (200 mL × 3) was extracted, and the organic phases were combined. The organic phase was washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The crude product was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1-0 / 1, volume ratio) to obtain compound c. 1 H NMR(400MHz, CDCl3)δ:8.42(s,1H),7.61(s,1H),4.64-4.55(m,2H),4.06-3.96(m,2H),3.42-3.25(m,1H),1.54-1.38(m,2H),1.19-1.08(m,2H)

[0244] Step 3: Synthesis of compound d

[0245] At room temperature and nitrogen atmosphere, 3,4-methylenedioxyphenylboronic acid pinacol ester (7.26g), compound c (3.3g) and potassium hydroxide (1.64g) were dissolved in anhydrous ethanol (100mL) and water (10mL), 1,1-bis(diphenylphosphino)ferrocenepalladium chloride (357.01mg) was added thereto, nitrogen was replaced three times, and the reaction temperature was raised to 85°C and stirred for 12 hours. After the reaction was completed, the mixture was cooled to room temperature, concentrated under reduced pressure to remove the solvent, diluted with water (30mL), filtered, and the filtrate was collected. The filtrate was adjusted to pH 3-4 with 3M dilute hydrochloric acid solution, extracted with ethyl acetate (50mL×3), the organic phases were combined, saturated brine (50mL×2) was added in turn for washing, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The crude product was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 0-1 / 1, volume ratio) to obtain compound d. 1 H NMR (400MHz, CDCl3) δ: 8.51 (s, 1H), 7.11-6.97 (m, 1H), 6.93 (d, J = 8.3Hz, 1H), 6.80-6.74 (m, 2H), 6.05 ( s,2H),4.53-4.45(m,2H),3.89-3.81(m,2H),3.53-3.24(m,1H),1.44-1.34(m,2H),1.15-1.06(m,2H).

[0246] Step 4: Synthesis of Compound II

[0247] At room temperature and under nitrogen atmosphere, sodium hydride (109.60 mg, 60% content) was dissolved in anhydrous tetrahydrofuran (20 mL), and compound d (130.00 mg) dissolved in a mixed solvent of anhydrous tetrahydrofuran (2 mL) and N,N-dimethylformamide (2 mL) was added at 25°C. Then, 5-bromo-2-chloropyrimidine (132.56 mg) dissolved in anhydrous tetrahydrofuran (2 mL) was added, and the reaction system was heated to 70°C and stirred for 2 hours. After the reaction was completed, the reaction system was cooled to room temperature, saturated ammonium chloride solution (10 mL) was added to quench the reaction, 2M dilute hydrochloric acid was used to adjust the pH to 4, ethyl acetate (40 mL×3) was used for extraction, and the organic phases were combined. The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The obtained residue was separated and purified by preparative HPLC (mobile phase: acetonitrile / water; neutral: NH4HCO3) to obtain the compound of formula (II). MS-ESI m / z: 536.1, 538.1 [M+H] + . 1H NMR (400MHz, CDCl3) δ: 8.50 (s, 3H), 6.98 (s, 1H), 6.86 (d, J = 8.5Hz, 1H), 6.76–6.69 (m, 2H), 6.03 (s, 2H),4.77–4.71(m,2H),4.68–4.63(m,2H),3.47–3.26(m,1H),1.43–1.34(m,2H),1.15–1.05(m,2H).

[0248] Example 2: Preparation of compound of formula (III)

[0249]

[0250] Step 1: Synthesis of compound III

[0251] At room temperature and under nitrogen protection, compound d (200 mg) was dissolved in anhydrous tetrahydrofuran (3 mL), cesium carbonate (721.40 mg) was added, 2,5-dichloropyrimidine (102.10 mg) was added at 25 ° C, and the reaction system was heated to 75 ° C and stirred for 12 hours. After the reaction was completed, the reaction system was cooled to room temperature, diluted with water (10 mL), and the pH was adjusted to 3-4 with 3M dilute hydrochloric acid. Ethyl acetate (15 mL × 3) was extracted and the organic phases were combined. The organic phase was washed with saturated brine (10 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The obtained residue was separated and purified by preparative HPLC (mobile phase: acetonitrile / water; neutral: NH4HCO3) to obtain the compound of formula (III). MS-ESI m / z: 492.1 [M + H] + . 1 H NMR(400MHz, DMSO_d6)δ:9.90(s,1H),8.66(s,2H),8.50(s,1H),6.90(d,J=8.0Hz,1H),6.77–6.62 (m,2H),6.03(s,2H),4.69–4.63(m,2H),4.62–4.58(m,2H),3.33–3.31(m,1H),1.09–0.97(m,4H).

[0252] Example 3: Preparation of the compound of formula (IV)

[0253]

[0254] Step 1: Synthesis of Compound IV

[0255] At room temperature and under nitrogen protection, compound d (124 mg) was dissolved in anhydrous tetrahydrofuran (1 mL), cesium carbonate (447.27 mg) was added, 2-chloro-5-(trifluoromethyl)-pyrimidine (102.10 mg) was added at 25°C, and the reaction system was heated to 75°C and stirred for 12 hours. After the reaction was completed, the reaction system was cooled to room temperature, diluted with water (10 mL), and the pH was adjusted to 3-4 with 3M dilute hydrochloric acid, extracted with ethyl acetate (15 mL×3), and the organic phases were combined. The organic phase was washed with saturated brine (10 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The obtained residue was separated and purified by preparative HPLC (mobile phase: acetonitrile / water; acidic: HCl) to obtain the compound of formula (IV). MS-ESI m / z: 526.1[M+H] + . 1 H NMR(400MHz, DMSO_d6)δ:9.91(s,1H),9.02(d,J=0.8Hz,2H),8.51(s,1H),6.89(d,J=8.0H z,1H),6.75-6.64(m,2H),6.02(s,2H),4.70(s,4H),3.30-3.25(m,1H),1.11-0.95(m,4H).

[0256] Example 4: Preparation of the compound of formula (V)

[0257]

[0258]

[0259] Step 1: Synthesis of compound e

[0260] At room temperature and under the protection of nitrogen, 2-chloro-5-bromopyrimidine (14 g) was dissolved in tetrahydrofuran (210 mL), and potassium carbonate (47.01 g) was added. After the reaction system was heated to 45°C, ethylene glycol (6.74 g) was added and stirred at 45°C for 12 hours. After the reaction was completed, the reaction solution was poured into water (500 mL) for quenching, extracted with ethyl acetate (200 mL × 3), the organic phase was washed with saturated brine (500 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent to obtain compound e, and the crude product was directly used for the next step.

[0261] Step 2: Synthesis of compound g

[0262] At room temperature and under the protection of nitrogen, compound f (5g) was dissolved in anhydrous toluene (75mL), and diethyl malonate (4.38g), tri-tert-butylphosphine (2.01g, 10%-14% toluene solution) and potassium phosphate (15.84g) were added thereto at 25°C. After replacing nitrogen three times, bis(dibenzylideneacetone)palladium (286.05mg) was added. After replacing nitrogen again, the reaction system was heated to 70°C and stirred for 12 hours. After the reaction was completed, 3M dilute hydrochloric acid was used to adjust the pH to 5-6, water (50mL) was added for dilution, ethyl acetate (80mL×3) was used for extraction, and the organic phases were combined. The organic phase was washed with saturated brine (50mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The crude product was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 0–4 / 1, volume ratio) to obtain compound g. 1 H NMR(400MHz, DMSO_d6)δ:6.95(d,J=1.8Hz,1H),6.83–6.73(m,2H),5.94(s,2H),4.51(s,1H),4.26–4.15(m,4H),1.28–1.23(m,6H).

[0263] Step 3: Synthesis of compound h

[0264] At room temperature and under nitrogen protection, sodium ethoxide (1.04 g) was dissolved in anhydrous ethanol (2.5 mL), and formamidine acetate (144.87 mg) was added. The reaction system was stirred at 25°C for 20 minutes, and compound g (0.3 g) dissolved in anhydrous ethanol (1.1 mL) was added. After the addition was completed, the reaction system was stirred at 25°C for 12 hours. After the reaction was completed, the reaction system was directly concentrated under reduced pressure to remove the solvent, diluted with water (5 mL), and 3M dilute hydrochloric acid was added to adjust the pH to 6-7, filtered, and the solid was collected. The solid was vacuum dried to remove the solvent to obtain compound h, and the crude product was directly used in the next step.

[0265] Step 4: Synthesis of Compound i

[0266] At room temperature and under nitrogen protection, compound h (110 mg) was dissolved in phosphorus oxychloride (0.5 mL), and the reaction system was heated to 90 ° C and stirred for 1 hour. After the reaction was completed, the reaction system was cooled to room temperature and slowly poured into water (5 mL) to quench, and the pH was adjusted to 7-8 with ammonia water. Dichloromethane (5 mL × 3) was extracted, the organic phases were combined, washed with saturated brine (10 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The crude product was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 0–5 / 1, volume ratio) to obtain compound i. 1H NMR (400MHz, CDCl3) δ: 8.77 (s, 1H), 6.95 (d, J = 8.3Hz, 1H), 6.82–6.73 (m, 2H), 6.08 (s, 2H).

[0267] Step 5: Synthesis of compound j

[0268] At room temperature and under nitrogen protection, compound i (92.7 mg) was dissolved in anhydrous toluene (3 mL), and compound e (67.91 mg) was added. The reaction system was cooled to 0°C, potassium tert-butoxide (77.31 mg) was added and stirred at 0°C for 0.5 hours. After the reaction was completed, 3M dilute hydrochloric acid was used to adjust the pH to 4-5, water (10 mL) was added for dilution, ethyl acetate (15 mL × 3) was used for extraction, the organic phases were combined, washed with saturated brine (10 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The crude product was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 0–5 / 1, volume ratio) to obtain compound j. 1 H NMR(400MHz, CDCl3)δ:8.59–8.46(m,3H),6.87–6.81(m,1H),6.79–6.75(m,2H),6.02(s,2H),4.80–4.73(m,2H),4.71–4.65(m,2H).

[0269] Step 6: Synthesis of Compound 1

[0270] At room temperature and under nitrogen atmosphere, compound k (1 g) was dissolved in dichloromethane (15 mL), and the reaction system was cooled to 0 ° C. Sodium cyanoborohydride (1.87 g) was added to the reaction system in batches, and two drops of acetic acid were added after the addition was completed. The reaction system was stirred at 20 ° C for 12 hours. After the reaction was completed, a saturated aqueous solution of ammonium chloride (50 mL) was poured into the reaction system to quench the reaction, and the organic phase was collected by separation. The aqueous phase was extracted with dichloromethane (20 mL × 3), and the organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The obtained residue was separated and purified by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 0–3 / 2, volume ratio) to obtain compound l. 1 HNMR(400MHz, CDCl3)δ:4.23–4.11(m,1H),3.67(s,3H),3.10–2.96(m,1H),2.54–2 .44(m,1H),2.41–2.26(m,3H),2.25–2.13(m,2H),1.99–1.84(m,2H),1.72(s,1H).

[0271] Step 7: Synthesis of Compound M

[0272] At room temperature and under nitrogen protection, compound l (927 mg) was dissolved in dichloromethane (15 mL), and 1,8-bis(dimethylamino)naphthalene (4.79 g) and trimethyloxonium tetrafluoroborate (2.50 g) were added in sequence at 25 ° C. The reaction system was stirred at 25 ° C for 2 hours. After the reaction was completed, the reaction system was filtered, the filter cake was rinsed with dichloromethane (10 mL), and the filtrate was combined. The filtrate was adjusted to pH 2-3 with 1M dilute hydrochloric acid, separated, the organic phase was collected, the aqueous phase was extracted with dichloromethane (30 mL), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was directly concentrated under reduced pressure to remove the solvent. The obtained residue was separated and purified by column chromatography (eluent: petroleum ether / ethyl acetate = 19 / 1-17 / 3, volume ratio) to obtain compound m. 1 H NMR(400MHz, CDCl3)δ:3.80–3.70(m,1H),3.66(s,3H),3.20(s,3H),3.08–2.99(m,1H),2.45–2.35(m,1H),2.34–2.11(m,5H),1.99–1.83(m,2H).

[0273] Step 8: Synthesis of Compound N

[0274] At room temperature and under nitrogen atmosphere, compound m (880 mg) was dissolved in a mixed solvent of tetrahydrofuran (10 mL), methanol (3 mL) and water (3 mL). Lithium hydroxide monohydrate (501.11 mg) was added to the reaction system and stirred at 20°C for 12 hours. After the reaction was completed, the reaction system was directly concentrated under reduced pressure to remove the solvent, the obtained residue was diluted with water (10 mL), the pH was adjusted to 2-3 with 1M dilute hydrochloric acid, and extracted with ethyl acetate (30 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent to obtain compound n, and the crude product was directly used in the next step.

[0275] Step 9: Synthesis of Compound O

[0276] At room temperature and nitrogen atmosphere, compound n (380 mg) was dissolved in dichloromethane (6 mL), and N-methylmorpholine (245.46 μL) was added. The reaction system was cooled to -15 ° C under nitrogen protection, and isobutyl chloroformate (293.19 μL) was added dropwise. After the addition was completed, the reaction system was stirred at 0 ° C for half an hour. Sodium thiopyridine nitrogen oxide (365.97 mg) was added to the reaction system under light protection conditions and stirred at 0 ° C for 2 hours in the dark. After the reaction was completed, the reaction system was directly concentrated under reduced pressure to remove the solvent to obtain compound o, and the crude product was directly used for the next step.

[0277] Step 10: Synthesis of Compound P

[0278] At room temperature and under a nitrogen atmosphere, compound o (623 mg) was dissolved in chlorobenzene (15 mL), 2,2-dipyridyl disulfide (737.00 mg) was added, and the mixture was irradiated under a metal halide lamp (500 W) for 2 hours under a nitrogen atmosphere. The reaction solution was directly concentrated to remove the solvent, and the obtained crude product was separated and purified by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 0–47 / 3, volume ratio) to obtain compound p. 1 H NMR(400MHz, CDCl3)δ:8.47–8.35(m,1H),7.49–7.45(m,1H),7.07(d,J=8.0Hz,1H),6.98–6.95(m,1H),4.24–4.16(m,1H),3. 82–3.75(m,1H),3.21(s,3H),2.66–2.53(m,2H),2.52–2.46(m,1H),2.38–2.30(m,1H),2.19–2.11(m,2H),2.04–1.94(m,2H).

[0279] Step 11: Synthesis of compound q

[0280] At room temperature and nitrogen atmosphere, compound p (205 mg) was dissolved in dichloromethane (5 mL), and the temperature was lowered to 0 ° C under nitrogen atmosphere. Meta-chloroperbenzoic acid (530.53 mg, content 85%) was added to the reaction system in batches and stirred at room temperature for 2 hours. After the reaction was completed, dichloromethane (10 mL) was added to the reaction system for dilution, saturated sodium bisulfite saturated aqueous solution (10 mL) was added, and the reaction was quenched by stirring for 10 min. The liquid was separated, and the organic phase was collected. The organic phase was washed with 1M sodium hydroxide aqueous solution (10 mL), saturated brine (5 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The crude product was separated and purified by column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 0–9 / 1, volume ratio) to obtain compound q. 1 HNMR(400MHz, CDCl3)δ:8.77–8.66(m,1H),8.07(d,J=8.0Hz,1H),7.98–7.91(m,1H),7.60–7.47(m,1H),4.30–4.18( m,1H),3.83–3.71(m,1H),3.20(s,3H),2.72–2.57(m,2H),2.47–2.34(m,2H),2.33–2.15(m,2H),2.03–1.90(m,2H).

[0281] Step 12: Synthesis of compound r

[0282] At room temperature and nitrogen atmosphere, tetrahydrofuran (3 mL) was placed in a reaction bottle, cooled to 0°C under nitrogen atmosphere, and sodium hydride (36.35 mg, content 60%) was added. Ethyl mercaptan (89.64 μL) was added dropwise to the reaction system at 0°C, and stirred at 0°C for 1 hour after the addition was complete. Compound q (162 mg) dissolved in (1 mL) tetrahydrofuran was added to the reaction system and stirred at room temperature for 12 hours. After the reaction was completed, methyl tert-butyl ether (2 mL) was added to the reaction system for dilution, filtered, and the filter cake was rinsed with methyl tert-butyl ether (2 mL). The filter cake was collected and vacuum dried to remove the solvent to obtain compound r, and the crude product was directly used for the next step.

[0283] Step 13: Synthesis of Compound S

[0284] At room temperature and under nitrogen atmosphere, compound r (70 mg) was dissolved in water (2 mL), potassium acetate (40.46 mg) and hydroxylamine sulfonic acid (46.62 mg) were added, and the reaction system was stirred at room temperature for 12 hours. After the reaction was completed, the reaction system was directly concentrated under reduced pressure to remove the solvent. The crude product was separated and purified by column chromatography (eluent: dichloromethane / methanol = 1 / 0-9 / 1, volume ratio) to obtain compound s. 1 H NMR(400MHz, DMSO_d6)δ:6.69(s,2H),3.79–3.53(m,1H),3.08(s,3H),2.97–2.93(m,1H),2.38–2.16(m,6H),1.88–1.73(m,2H).

[0285] Step 14: Synthesis of Compound V

[0286] Compound j (60.01 mg) and compound s (30 mg) were dissolved in dimethyl sulfoxide (1.5 mL) at room temperature and under a nitrogen atmosphere. 1M tetrabutylammonium fluoride in tetrahydrofuran solution (265.72 μL) and potassium carbonate (55.09 mg) were added to the reaction system in sequence, and the temperature was raised to 70°C and stirred for 5 hours under a nitrogen atmosphere. After the reaction was completed, the reaction system was cooled to room temperature, the pH was adjusted to 3-4 with 1M dilute hydrochloric acid, and extracted with ethyl acetate (30 mL×3). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The crude product was separated and purified by preparative HPLC (mobile phase: acetonitrile / water; acidic: HCl) to obtain a compound of formula (V). MS–ESI m / z: 619.8, 621.9 [M+H] + . 1H NMR(400MHz, DMSO_d6)δ:9.81(s,1H),8.70(s,2H),8.47(s,1H),6.90(d,J=8.0Hz,1H),6.72–6.62(m,2H),6.03(s ,2H),4.69–4.55(m,4H),4.54–4.39(m,1H),3.73–3.62(m,1H),3.06(s,3H),2.42–2.16(m,6H),1.88–1.73(m,2H).

[0287] Example 5: Preparation of the compound of formula (VI)

[0288]

[0289] Step 1: Synthesis of compound t

[0290] Sodium methoxide (11.57 g) was dissolved in ethanol (50 mL) at room temperature and under the protection of nitrogen. Acetamidine hydrochloride (2.63 g) was added and stirred at 25°C for 20 minutes. A solution of compound g (6 g) in ethanol (24 mL) was added to the reaction system and stirred at 25°C for 3 hours. After the reaction was completed, the reaction system was directly concentrated under reduced pressure to remove the solvent. The obtained residue was diluted with water (50 mL) and filtered. The filtrate was adjusted to pH 2-3 with 3M dilute hydrochloric acid, stirred for 10 minutes, filtered, and the filter cake was collected. The filter cake was vacuum dried to remove the solvent to obtain compound t. 1 H NMR(400MHz, DMSO_d6)δ:12.76–11.60(m,2H),7.18–7.02(m,2H),6.89–6.76(m,2H),5.95(s,1H),2.27(s,3H).

[0291] Step 2: Synthesis of Compound U

[0292] At room temperature and under the protection of nitrogen, compound t (2.8 g) was dissolved in phosphorus oxychloride (24.75 g), and the reaction system was heated to 90 ° C and stirred for 2 hours. After the reaction was completed, the reaction system was directly concentrated under reduced pressure, and the residue was dissolved in dichloromethane (50 mL), and the pH was adjusted to 8-9 with saturated sodium bicarbonate aqueous solution. The organic phase was collected, and the aqueous phase was extracted with dichloromethane (20 mL × 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The residue was separated and purified by column chromatography (eluent: petroleum ether / ethyl acetate = 19 / 1-9 / 1, volume ratio) to obtain compound u. MS-ESIm / z: 282.9, 284.8.

[0293] Step 3: Synthesis of compound w

[0294] At room temperature and under nitrogen protection, compound u (1.4 g) and compound e (974.83 mg) were dissolved in toluene (25 mL), and the temperature was lowered to 0 ° C under nitrogen protection. Potassium tert-butoxide (1.11 g) was added to the reaction system in batches and stirred at 0 ° C for 1 hour. After the reaction was completed, the reaction system was poured into water (10 mL) to quench the reaction, and the pH value was adjusted to 3-4 with 2M dilute hydrochloric acid. It was extracted with ethyl acetate (20 mL × 3), the organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The obtained residue was separated and purified by column chromatography (eluent: petroleum ether / ethyl acetate = 19 / 1–13 / 7, volume ratio). Compound w was obtained. 1 H NMR(400MHz, CDCl3)δ:8.50(s,2H),6.86–6.79(m,1H),6.78–6.70(m,2H),6.00(s,2H),4.80–4.71(m,2H),4.69–4.60(m,2H),2.59(s,3H).

[0295] Step 4: Synthesis of Compound VI

[0296] Compound w (1.5 g) and cyclopropanesulfonamide (429.28 mg) were dissolved in dimethyl sulfoxide (20 mL) at room temperature and under nitrogen protection. Tetrabutylammonium fluoride (1 M tetrahydrofuran, 6.44 mL) and potassium carbonate (1.34 g) were added to the reaction system, replaced with nitrogen three times, and heated to 70 ° C under nitrogen protection and stirred for 12 hours. After the reaction was completed, the reaction system was poured into water (10 mL) to quench the reaction, and the pH was adjusted to 3-4 with 3M dilute hydrochloric acid, extracted with ethyl acetate (20 mL × 2), the organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The obtained residue was separated by column chromatography (eluent: petroleum ether / ethyl acetate = 19 / 1-3 / 2, volume ratio) to obtain a crude product, which was then separated and purified by preparative HPLC (mobile phase: acetonitrile / water; acidic: HCl) to obtain a compound of formula (VI). MS–ESI m / z:549.8,551.8[M+H] + . 1 H NMR(400MHz, DMSO_d6)δ:9.73(s,1H),8.72(s,2H),6.90(d,J=8.0Hz,1H),6.76–6.50(m, 2H),6.03(s,2H),4.75–4.48(m,4H),3.31–3.23(m,1H),2.44(s,3H),1.13–0.90(m,4H).

[0297] Example 6: Preparation of amorphous compound of formula (IV)

[0298] The liquid containing the compound of formula (IV) obtained by preparative HPLC separation in Example 3 was concentrated under reduced pressure at 40-45° C. to remove acetonitrile, and then lyophilized to obtain an amorphous compound of formula (IV).

[0299] Example 7: Preparation of Crystalline Compound A of Formula (IV)

[0300] Take 300 mg of the compound of formula (IV), add 0.9 mL of tetrahydrofuran to dissolve, then slowly add 9.5 mL of n-heptane under stirring. Stir overnight at 25°C and centrifuge, and the residual solid sample is placed in a vacuum drying oven (30°C) and dried overnight to obtain a crystal A of the compound of formula (IV).

[0301] Example 8: Preparation of Crystalline Compound B of Formula (IV)

[0302] Take 300 mg of the compound of formula (IV), add 1.5 mL of acetone to dissolve, then slowly add 7.5 mL of n-heptane under stirring, stir overnight at 25°C and centrifuge, and place the residual solid sample in a vacuum drying oven (30°C) to dry overnight to obtain the crystal B of the compound of formula (IV).

[0303] Example 9: Preparation of Crystalline Compound C of Formula (IV)

[0304] Take 300 mg of the compound of formula (IV), add 0.9 mL of tetrahydrofuran to dissolve, then slowly add 9 mL of water under stirring, stir overnight at 25°C and centrifuge, and the residual solid sample is placed in a vacuum drying oven (30°C) and dried overnight to obtain the crystal C of the compound of formula (IV).

[0305] Test Example 1 In vitro test of human ETA receptor antagonist effect

[0306] Purpose:

[0307] The effects of compounds on human ET were determined by using a fluorescence detection method. A Agonist-induced cytosolic Ca 2+ Effects of changes in ion signals on the activity of compounds in endogenously expressed human ET in SK-N-MC cells A Antagonist activity on ET receptors. A Functional activity of receptor antagonists was tested at Eurofins-Cerep SA according to current standard operating procedures.

[0308] Experimental protocol:

[0309] 1. The cells (human endogenous (SK-N-MC cells)) were suspended in Dulbecco's modified Eagle's medium solution (DMEM, Invitrogen) supplemented with 1% FCSd, and then distributed in a 384 plate at a density of 5×104 cells / well (100 μL / well);

[0310] 2. Carboxybenzenesulfonamide was mixed with a fluorescent probe (Fluo4 NW, Invitrogen) in Hank's balanced salt solution (HBSS, Invitrogen) supplemented with 20 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (Hepes, Invitrogen) (pH 7.4), added to each well, and then equilibrated with the cells at 37°C for 60 minutes and then at 22°C for 15 minutes;

[0311] 3. The assay plate was placed in a microplate reader (CellLux, PerkinElmer), and appropriate concentrations of DMSO solution or HBSS buffer of the test compound and positive control were added. After 5 minutes, 1 nM endothelin-1 or HBSS buffer (basal control) was added, and the Ca2+-free cytosolic ... 2+ The change in fluorescence intensity is proportional to the ion concentration;

[0312] 4. Results are percent inhibition of the control response to 1 nM endothelin-1;

[0313] 5. The standard positive control is BQ-123 (CAS Registry Number: 136553-81-6). Several concentrations are tested in each experiment. The data are analyzed using Prism to generate a concentration-response curve and calculate the IC of the compound. 50 value.

[0314] Test Example 2 In vitro test of human ETB receptor antagonist effect

[0315] Purpose:

[0316] The effects of compounds on human ET were determined by using a fluorescence detection method. B Agonist-induced cytosolic Ca 2+ Ion signal changes to evaluate the effects of compounds in transfected CHO cells expressing human ET B Antagonist activity on ET receptors. B Functional activity of receptor antagonists was tested at Eurofins-Cerep SA according to current standard operating procedures.

[0317] Experimental protocol:

[0318] 1. Cells (human recombinant (CHO cells)) were suspended in DMEM buffer (Invitrogen) and then distributed in 384 plates at a density of 3×104 cells / well (100 μL / well);

[0319] 2. Carboxybenzenesulfonamide was mixed with a fluorescent probe (Fluo4 Direct, Invitrogen) in HBSS buffer (Invitrogen) supplemented with 20 mM Hepes (Invitrogen) (pH 7.4), added to each well, and then equilibrated with the cells at 37°C for 60 minutes and then at 22°C for 15 minutes;

[0320] 3. Place the assay plate in a microplate reader (CellLux, PerkinElmer), add the test compound and the appropriate concentration of DMSO solution or HBSS buffer of the positive control, and then add 0.3 nM endothelin-1 or HBSS buffer (basal control) after 5 minutes, and then measure the change in fluorescence intensity proportional to the free cytosolic Ca2+ ion concentration;

[0321] 4. Results are percent inhibition of the control response to 0.3 nM endothelin-1;

[0322] 5. The standard positive control is BQ-788 sodium salt (CAS Registry Number: 156161-89-6). Several concentrations were tested in each experiment. The data were analyzed using Prism to generate a concentration-response curve and calculate the IC50 value of the compound.

[0323] Experimental results: Some experimental results are shown in Table 5.

[0324] Table 5 Antagonistic activity data of the disclosed compounds on human ETA and ETB receptors and their selectivity for ETB receptors

[0325] Compound <![CDATA[ETA-IC 50 (nM)]]> <![CDATA[ETB-IC 50 (nM)]]> ETB / ETA selection coefficient Formula (II) 1.8 230000 127778 Formula (III) 6.5 84000 12923 Formula (IV) 3.3 >300000 >90909 Formula (V) 3.1 >100000 >32258 Formula (VI) 4.3 >100000 >23255

[0326] Experimental conclusion: The compounds disclosed in the present invention exhibited high inhibitory activity against human ETA receptors in in vitro experiments; at the same time, some compounds were highly selective for human ETA and ETB receptors, with a selectivity coefficient greater than 10,000 times.

[0327] Test Example 3 In vivo pharmacokinetic properties study

[0328] Experimental purpose: To determine the pharmacokinetic parameters of the compound in SD rats.

[0329] Experimental Materials:

[0330] Sprague Dawley rats (male, 200-300 g, 7-9 weeks old, Beijing Weitong Lihua)

[0331] Experimental methods:

[0332] 1. This project uses 4 male SD rats, which are weighed before administration. The dosage is calculated based on the body weight, and then the rats are divided into two groups. One group of 2 SD rats are intravenously injected with a dosage of 2 mg / kg and a concentration of 0.5 mg / mL; the other group of 2 SD rats are orally administered with a dosage of 10 mg / kg and a concentration of 1 mg / mL;

[0333] 2. Collect plasma samples at 0.083 (only intravenous group), 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours after administration. Each sample is about 0.05 mL, anticoagulated with sodium heparin, and placed on wet ice after collection.

[0334] 3. After blood samples were collected, they were placed on ice and centrifuged within 1 hour to separate plasma (centrifugation conditions: 6000g, 3 minutes, 2-8°C). Plasma samples were stored in a -80°C refrigerator before analysis.

[0335] 4. Perform LC-MS / MS analysis on the collected samples and collect data. The collected analytical data are used to calculate relevant pharmacokinetic parameters using PhoenixWinNonlin 8.2.0 software.

[0336] Experimental results: Some experimental results are shown in Table 6.

[0337] Table 6 In vivo pharmacokinetic experimental results

[0338]

[0339] Conclusion: The disclosed compounds have good exposure and bioavailability.

[0340] Test Example 4 In vivo efficacy study of the compound in the treatment of Thy1 nephritis

[0341] Experimental process:

[0342] 1. Fifty rats (SD rats, Changzhou Cavens Experimental Animal Co., Ltd.) were anesthetized with isoflurane gas. After general anesthesia, unilateral nephrectomy was performed on the right side of the rats; the right kidney was removed, and then sutured and antibiotics were given; the operation steps of the control group rats (Group-1) were the same as the model group, but the kidney was not removed. One week after unilateral nephrectomy, 1 mg / kg anti-Thy1 antibody was injected into the tail vein of the model group rats, and the same volume of normal saline was injected into the tail vein of the control group rats. On the third day after injection, 24-hour urine of the rats was collected to detect the total protein content in the urine; rats with unsuccessful modeling were eliminated, and the modeling rats were randomly divided into 6 groups according to the urine protein data using a simple random method, namely Group-2, Group-3, Group-4, Group-5, Group-6, and Group-7.

[0343] 2. On the fourth day after antibody injection, rats in Group-1 and Group-2 were gavaged with an equal volume of solvent (5% DMSO + 20% PEG400 + 10% HS) once a day with a gavage volume of 1 mL / 100 g for 4 consecutive weeks; rats in Group-3 were gavaged with 5 mg / kg prednisone once a day with a gavage volume of 1 mL / 100 g for 4 consecutive weeks; rats in Group-4 were gavaged with atrasentan (10 mg / kg) once a day with a gavage volume of 1 mL / 100 g. g, for 4 consecutive weeks; rats in Group-5 were gavaged with the embodiment compound of the present disclosure (1 mg / kg) once a day, with a gavage volume of 1 mL / 100 g, for 4 consecutive weeks; rats in Group-6 were gavaged with the embodiment compound of the present disclosure (3 mg / kg) once a day, with a gavage volume of 1 mL / 100 g, for 4 consecutive weeks; rats in Group-7 were gavaged with the embodiment compound of the present disclosure (10 mg / kg) once a day, with a gavage volume of 1 mL / 100 g, for 4 consecutive weeks.

[0344] 3. On the third day (Day 0) after antibody injection, the 7th day after administration, and the 28th day after administration, the 24-hour urine of the rats was collected to detect the 24-hour urine protein content; after the urine collection was completed, blood samples were taken from the rats in each group to detect the hematocrit.

[0345] 4. After blood collection, the rats were euthanized by CO2 method, and the kidney tissue was obtained and PAS staining was used to observe the degree of kidney tissue lesions.

[0346] Statistical analysis:

[0347] Data were analyzed and plotted using Graphpad Prism 5 (Version 5.01), and Adobe Illustrator CS6 (Version 16.0.0) was used to organize and combine the figures. All data are expressed as means±SD, and statistical differences between groups were analyzed using one-way ANOVA and Tukey's test. P values ​​less than 0.05 were considered to be significantly different.

[0348] Experimental conclusion: The disclosed compounds can reduce the proteinuria content in rats, increase the hematocrit, and alleviate the renal damage in rats, inhibiting the proliferation of glomerular mesangial cells, the increase of glomerular mesangial matrix and the thickening of glomerular capsule wall.

[0349] Test Example 5: Study on the Hygroscopicity of Compound Crystals

[0350] Experimental Materials:

[0351] SMSDVS Advantage Dynamic Vapor Sorption Tester

[0352] Experimental methods:

[0353] 10-15 mg of the compound of the present embodiment was placed in a DVS sample pan for testing.

[0354] Conclusion: The weight gain of the crystal A of the present invention at 25°C and 80% relative humidity is about 0.027%, and it has no or almost no hygroscopicity.

[0355] Test Example 6: Solid Stability Test of Compound Crystals

[0356] According to the "Guidelines for Stability Testing of APIs and Preparations" (Chinese Pharmacopoeia 2015 Edition Part IV General Rules 9001), the stability of the crystals of the compounds in the embodiments of the present invention under high temperature (60°C, open), high humidity (room temperature / relative humidity 92.5%, open) and strong light (5000lx, sealed) conditions was investigated.

[0357] Weigh 15 mg of the crystals of the compound of the embodiment of the present disclosure, place them at the bottom of a glass sample bottle, and spread them into a thin layer. For samples placed under high temperature and high humidity conditions, seal the bottle mouth with aluminum foil, and poke some small holes in the aluminum foil to ensure that the sample can fully contact with the ambient air; for samples placed under strong light conditions, seal them with a threaded bottle cap. Samples placed under different conditions are sampled and tested (XRPD) on the 5th and 10th days, and the test results are compared with the initial test results on day 0.

[0358] Conclusion: Crystal A has good stability under high temperature, high humidity and strong light conditions.

Claims

1. A crystal of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in, Z 1 Select from N or CR Z1 ; Z 2 Select from N or CR Z2 ; R Z1 or R Z2 Each is independently selected from H, halogen, -OH, -NH2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, di-C 1-6 Alkylamino, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, halogenated C 1-6 Alkylthio, halo 1-6 Alkylamino, or halogenated di-C 1-6 Alkylamino; X is selected from O or NH; Ring A is selected from optionally substituted with one or more R a Substituted: 3-12 membered cycloalkyl or 3-12 membered heterocycloalkyl; R a are each independently selected from halogen, -OH, oxo, -NH2, -CN, -C(O)R a1 、-C(O)NR a1 R a2 、-NR a1 C(O)R a2 、-NHC(O)NR a1 R a2 、-NR a1 C(O)OR a2 、-OC(O)R a1 、-C(O)OR a1 、-OC(O)OR a1 、-OC(O)NR a1 R a2 , -C 1-6 Alkylene C(O)NR a1 R a2 , -C 1-6 Alkylene NR a1 C(O)R a2 , -C 1-6 AlkyleneNHC(O)NR a1 R a2 , -C 1-6 Alkylene NR a1 C(O)OR a2 , -C 1-6 Alkylene OC(O)R a1 , -C 1-6 Alkylene C(O)OR a1 , -C 1-6 Alkylene OC(O)NR a1 R a2 , or optionally one or more R a3 Substituted with the following groups: C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 5-10 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl; R a1 , R a2 Each independently selected from H or C 1-6 alkyl; R a3 Each is independently selected from halogen, -OH, -NH2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, di-C 1-6 Alkylamino, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, halogenated C 1-6 Alkylthio, halo 1-6 Alkylamino, or halogenated di-C 1-6 Alkylamino; L is selected from a single bond, -O-, -S-, -NH-, -C(O)-, or optionally substituted by one or more R L Substituted with the following groups: -CH2-, -N(C 1-6 alkyl)-, or -CH(C 1-6 alkyl)-; R L Each is independently selected from halogen, -OH, -NH2, -CN, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, di-C 1-6 Alkylamino, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, halogenated C 1-6 Alkylthio, halo 1-6 Alkylamino, or halogenated di-C 1-6 Alkylamino; Ring D is selected from optionally one or more R b Substituted: 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 5-10 membered carbocyclyl, 5-10 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl; R b Each is independently selected from halogen, -OH, -NH2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, di-C 1-6 Alkylamino, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, halogenated C 1-6 Alkylthio, halo 1-6 Alkylamino, or halogenated di-C 1-6 Alkylamino; Y 1 is selected from -O-, -S-, or -NH-; Y 2 is selected from -O-, -S-, -NH-, -SO2-, -NHSO2-, -SO2NH-, -NHSO2NH-, -C(O)NH-, -NHC(O)-, -OC(O)NH-, -NHC(O)O-, or -NHC(O)NH-; m is selected from 1, 2, 3, 4, 5, or 6; Ring C is selected from 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 5-10 membered carbocyclyl, 5-10 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl; n is selected from 0, 1, 2, 3, or 4; R1 is independently selected from halogen, -OH, -NH2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, di-C 1-6 Alkylamino, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, halogenated C 1-6 Alkylthio, halo 1-6 Alkylamino, or halogenated di-C 1-6 Alkylamino; R2 is selected from H, halogen, -OH, -NH2, -CN, or is optionally replaced by one or more R 2a Substituted with the following groups: C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, di-C 1-6 Alkylamino, 3-12 membered cycloalkyl, 3-12 membered heterocycloalkyl, 5-10 membered carbocyclyl, 5-10 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl; R 2a Each is independently selected from oxo, halogen, -OH, -NH2, -CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, di-C 1-6 Alkylamino, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, halogenated C 1-6 Alkylthio, halo 1-6 Alkylamino, or halogenated di-C 1-6 Alkylamino; R Z1 , R Z2 ,X,R a , R a1 , R a2 , R a3 , R L , R b , R1, R2, R 2a , Ring A, Ring D or Ring C is optionally substituted with one or more substituents.

2. The crystal according to claim 1, wherein the crystal of the compound of formula (I) or a pharmaceutically acceptable salt thereof is selected from the crystal of the compound of formula (II), the compound of formula (III), the compound of formula (IV), the compound of formula (V) or the compound of formula (VI), 3. Crystalline A of the compound of formula (IV), which has diffraction peaks at the following 2θ angles in its X-ray powder diffraction pattern using Cu Kα radiation: 16.82±0.20°, 17.61±0.20°, 19.31±0.20°; Alternatively, an X-ray powder diffraction pattern using Cu Kα radiation has diffraction peaks at the following 2θ angles: 16.82±0.20°, 17.61±0.20°, 19.31±0.20°, 20.53±0.20°, 24.35±0.20°; Alternatively, the X-ray powder diffraction pattern using Cu Kα radiation, expressed as 2θ angle, comprises at least 6, 7 or 8 diffraction peaks selected from the following: 16.82±0.20°, 17.61±0.20°, 18.31±0.20°, 19.31±0.20°, 20.53±0.20°, 21.46±0.20°, 22.35±0.20°, 24.35±0.20°; Alternatively, the X-ray powder diffraction pattern using Cu Kα radiation has diffraction peaks at the following 2θ angles: 12.14±0.20°, 16.82±0.20°, 17.61±0.20°, 18.31±0.20°, 19.31±0.20°, 20.53±0.20°, 21.46±0.20°, 22.35±0.20°, 23.21±0.20°, 24.35±0.20°, 25.21±0.20°, 26.32±0.20°, 27.18±0.20°, 28.38±0.20°.

4. The crystal A of the compound of formula (IV) according to claim 3, wherein the differential scanning calorimetry curve has an endothermic peak starting value at 147.29°C±3°C and an exothermic peak starting value at 177.45°C±3°C.

5. Crystalline B of the compound of formula (IV), which has diffraction peaks at the following 2θ angles in its X-ray powder diffraction pattern using Cu Kα radiation: 16.92±0.20°, 19.40±0.20°, 24.38±0.20°; Alternatively, an X-ray powder diffraction pattern using Cu Kα radiation has diffraction peaks at the following 2θ angles: 16.92±0.20°, 17.70±0.20°, 18.35±0.20°, 19.40±0.20°, 24.38±0.20°; Alternatively, the X-ray powder diffraction pattern using Cu Kα radiation, expressed as 2θ angle, comprises at least 6, 7, 8 or 9 diffraction peaks selected from the following: 14.20±0.20°, 16.92±0.20°, 17.70±0.20°, 18.35±0.20°, 19.40±0.20°, 20.42±0.20°, 21.50±0.20°, 22.37±0.20°, 24.38±0.20°; Alternatively, the X-ray powder diffraction pattern using Cu Kα radiation has diffraction peaks at the following 2θ angles: 14.20±0.20°, 16.92±0.20°, 17.70±0.20°, 18.35±0.20°, 19.40±0.20°, 20.42±0.20°, 21.50±0.20°, 22.37±0.20°, 24.38±0.20°, 26.58±0.20°, 27.23±0.20°.

6. The crystal B of the compound of formula (IV) according to claim 5, wherein the differential scanning calorimetry curve has an endothermic peak starting value at 142.02°C±3°C and an exothermic peak starting value at 177.72°C±3°C.

7. Crystalline C of the compound of formula (IV), which has diffraction peaks at the following 2θ angles in its X-ray powder diffraction pattern using Cu Kα radiation: 12.38±0.20°, 14.23±0.20°, 17.93±0.20°, 20.44±0.20°; Alternatively, an X-ray powder diffraction pattern using Cu Kα radiation has diffraction peaks at the following 2θ angles: 7.14±0.20°, 10.01±0.20°, 12.38±0.20°, 14.23±0.20°, 17.93±0.20°, 20.44±0.20°; Alternatively, the X-ray powder diffraction pattern using Cu Kα radiation is expressed by 2θ angles and comprises at least 9, 10, 11 or 12 diffraction peaks selected from the following: 7.14±0.20°, 8.12±0.20°, 10.01±0.20°, 12.38±0.20°, 14.23±0.20°, 16.88±0.20°, 17.93±0.20°, 20.11±0.20°, 20.44±0.20°, 20.86±0.20°, 21.38±0.20°, and 26.62±0.20°.

8. The crystal C of the compound of formula (IV) as claimed in claim 7, wherein the differential scanning calorimetry curve of the crystal has an endothermic peak starting value at 142.30°C±3°C and an exothermic peak starting value at 176.16°C±3°C.

9. A crystalline composition comprising a crystal of a compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein: The crystals account for more than 50% by weight of the crystalline composition, preferably more than 80%, more preferably more than 90%, and most preferably more than 95%.

10. A pharmaceutical composition comprising a therapeutically effective amount of a crystal of a compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, or a crystalline composition according to claim 9, wherein the pharmaceutical composition is prepared as a pharmaceutical composition having a single dose of 0.001 to 10000 mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof.

11. Use of the crystal of the compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, or the crystalline composition according to claim 9, or the pharmaceutical composition according to claim 10 in the preparation of a medicament for treating a disease, wherein the disease is selected from ETA receptor-related diseases; Alternatively, the disease is selected from IgA nephropathy.